Answers are grounded in this paper and cite their sources.
RSPO3 fusion activates the Wnt/β-catenin pathway at the level of upstream Wnt ligands, rather than directly through APC / CTNNB1 mutations. Beyond colorectal carcinoma, RSPO3 fusions remain underexplored. Herein, we report the first case series of PTPRK :: RSPO3 fusion-positive small intestinal adenocarcinoma. Among 115 genomically profiled small intestinal adenocarcinomas, 5 (4%) patients were identified, including 4 (80%) women and 1 (20%) man, aged 51 to 69 years (mean = 59), of African American (4/5; 80%) and White (1/5; 20%) ethnicity. Tumors arose from the jejunum (4/5; 80%) and duodenum (1/5; 20%), with a mean size of 4.7 cm. All tumors were adenocarcinoma, not otherwise specified, with mucinous features in 2/5 (40%), presenting at pT4 with lymphovascular and perineural invasion, and were mismatch repair-proficient/microsatellite stable, ERBB2 (HER2)-negative, and PD-L1 (CD274)-negative, with low tumor mutation burden and loss of heterozygosity. All fusion transcripts resulted from an in-frame PTPRK exon 1:: RSPO3 exon 2 fusion. The molecular landscape demonstrated frequent mutations in TP53 (5/5 [100%]) and the MAPK pathway genes ( KRAS , NRAS , BRAF ; 4/5 [80%]), while being APC / CTNNB1 / RNF43 -wild-type. Despite multimodal therapy, all patients developed metastasis (peritoneum 5/5 [100%]; liver 4/5 [80%]), with a mean overall survival of 28.5 months. PTPRK :: RSPO3 fusion defines a subset of small intestinal adenocarcinomas that shares a core molecular profile with its colorectal counterpart, exhibits aggressive behavior, and is a candidate for emerging Wnt-targeted therapies. Including RNA-based testing in the molecular profiling of small intestinal adenocarcinoma can identify rare yet targetable fusion genes that may inform patient selection for clinical trials.
No takes yet. Share an insight, caveat, or question.
Haw et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: